Needham analyst Joseph Stringer downgraded Inozyme (INZY) to Hold from Buy without a price target after BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire the company for $4.00 per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme downgraded to Equal Weight from Overweight at Wells Fargo
- Inozyme Pharma’s INZ-701 Shows Promising Results in ENERGY-3 Study, Highlighting Investment Potential
- BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
- Inozyme downgraded to Neutral from Outperform at Wedbush
- Inozyme Pharma Merges with BioMarin for $270 Million